Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time

Rhea-AI Summary

Lantheus Holdings, Inc. (NASDAQ: LNTH) will host a conference call and webcast on July 28, 2021, at 8:00 a.m. ET to discuss its Q2 2021 financial and operational results. Investors can join the call by dialing U.S. 1-866-498-8390 or international 1-678-509-7599, using passcode 6149638. The live webcast will be accessible on the company's website, with a replay available after the call and archived for 30 days. Lantheus specializes in innovative imaging diagnostics and therapeutics, offering a broad product portfolio, including DEFINITY®, PYLARIFY®, and RELISTOR®.

Positive

• Company will provide financial insights in the upcoming Q2 2021 call.
• Lantheus has a diverse portfolio of innovative medical imaging and therapeutic products.

Negative

• None.

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021, to discuss its financial and operating results for the second quarter of 2021.

To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 6149638. A live webcast will also be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the webcast will be available in the Investors section of the Company’s website approximately two hours after completion of the call and will be archived for 30 days.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find Fight and Follow^® serious medical conditions. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY^® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY^®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite^® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA^® for the treatment of certain rare neuroendocrine tumors; and RELISTOR^® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Canada and Sweden. For more information, visit www.lantheus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005300/en/

FAQ

When will Lantheus Holdings discuss its Q2 2021 results?

Lantheus Holdings will discuss its Q2 2021 results during a conference call on July 28, 2021, at 8:00 a.m. ET.

How can I access the Lantheus Holdings conference call?

The conference call can be accessed by dialing 1-866-498-8390 for U.S. callers or 1-678-509-7599 for international callers, using passcode 6149638.

Will there be a replay of the Lantheus Holdings conference call?

Yes, a replay of the conference call will be available approximately two hours after completion and will be archived for 30 days.

What products does Lantheus Holdings offer?

Lantheus Holdings offers products like DEFINITY®, PYLARIFY®, TechneLite®, AZEDRA®, and RELISTOR®.